. 2022 May 20;19(8):533–550. doi: 10.1038/s41575-022-00608-8

Table 3.

Antiviral combinations recommended by the EASL in DAA-naive patients with compensated liver disease in 2021

Cirrhosis status	Prior treatment	Glecaprevir–pibrentasvir	Sofosbuvir–velpatasvir
No cirrhosis	Naive	8 weeks	12 weeks
No cirrhosis	Peg-IFN + RBV
Compensated cirrhosis	Naive
Compensated cirrhosis	Peg-IFN + RBV	12 weeks

Data from ref.⁵. For a simplified treatment without the need for hepatitis C virus genotype, resistance-associated substitution or baseline viral load determination. DAA, direct-acting antiviral agent; EASL, European Association for the Study of the Liver; Peg-IFN, pegylated interferon-α; RBV, ribavirin.